A trial looking at MK-4280A for Hodgkin lymphoma
This trial is looking at a new drug called MK-4280A for Hodgkin lymphoma.
This trial is looking at a new drug called MK-4280A for Hodgkin lymphoma.
This trial is comparing standard treatment with 2 newer combinations of treatment to prevent GvHD.
This trial is looking at pembrolizumab after chemotherapy. It is open to children from 3 years old to young adults 25 years old with classical Hodgkin lymphoma.
This trial is comparing different ways of treating Hodgkin lymphoma to help lower the risk of long term side effects.
This trial is looking at having avelumab before standard chemotherapy for advanced Hodgkin lymphoma.
When diagnosed at its earliest stage, more than 9 in 10 (97%) people with Hodgkin lymphoma will survive their disease for one year or more, compared with almost 9 in 10 (87%) people when the disease is diagnosed at the latest stage.
This trial is looking at nivolumab for people whose Hodgkin lymphoma has come back after initial chemotherapy or it didn’t work well enough.
Since the early 1970s, Hodgkin lymphoma mortality rates have decreased by around three-quarters (74%) in the UK. Rates in females have decreased by more than seven-tenths (72%), and rates in males have decreased by around three-quarters (74%) (2017-2019).
Over the last decade, Hodgkin lymphoma mortality rates have remained stable in the UK. Rates in females have remained stable, and rates in males have remained stable (2017-2019).
Mortality rates for Hodgkin lymphoma in the UK are highest in people aged 85 to 89 (2017-2019).
Each year more than half of all Hodgkin lymphoma deaths (52%) in the UK are in people aged 75 and over (2017-2019).
There are around 310 Hodgkin lymphoma deaths in the UK every year, that's around 1 every day (2017-2019).
Hodgkin lymphoma is not among the 20 most common causes of cancer death in the UK, accounting for less than 1% of all cancer deaths (2017-2019).
In females in the UK, Hodgkin lymphoma is not among the 20 most common causes of cancer death, with around 130 deaths every year (2017-2019).
In males in the UK, Hodgkin lymphoma is not among the 20 most common causes of cancer death, with around 180 deaths every year (2017-2019).